UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Journal of hematology and oncology, 2021-07, Vol.14 (1), p.1-108, Article 108

2021

Volltextzugriff (PDF)

Next generation of immune checkpoint inhibitors and beyond

Journal of hematology and oncology, 2021-03, Vol.14 (1), p.45-29, Article 45

2021

Volltextzugriff (PDF)

Emerging therapeutic agents for advanced non-small cell lung cancer

Journal of hematology and oncology, 2020-05, Vol.13 (1), p.58-23, Article 58

2020

Volltextzugriff (PDF)

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Journal of hematology and oncology, 2018-03, Vol.11 (1), p.39-39, Article 39

2018

Volltextzugriff (PDF)

Emerging therapeutic agents for lung cancer

Journal of hematology and oncology, 2016-12, Vol.9 (1), p.138-138, Article 138

2016

Volltextzugriff (PDF)

Cancer immunotherapy beyond immune checkpoint inhibitors

Journal of hematology and oncology, 2018-01, Vol.11 (1), p.8-25, Article 8

2018

Volltextzugriff (PDF)

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (20), p.5209-5218

2012

Volltextzugriff (PDF)

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

JNCI : Journal of the National Cancer Institute, 2021-10, Vol.113 (10), p.1396-1404

2021

Volltextzugriff (PDF)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Frontiers in oncology, 2021-12, Vol.11, p.750657-750657

2021

Volltextzugriff (PDF)

Comprehensive Characterization of Alternative Polyadenylation in Human Cancer

JNCI : Journal of the National Cancer Institute, 2018-04, Vol.110 (4), p.379-389

2018

Volltextzugriff (PDF)

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Clinical cancer research, 2013-01, Vol.19 (2), p.393-403

2013

Volltextzugriff (PDF)

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

BMC genomics, 2018-08, Vol.19 (1), p.582-582, Article 582

2018

Volltextzugriff (PDF)

Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis

Scientific reports, 2024-02, Vol.14 (1), p.2782-2782, Article 2782

2024

Volltextzugriff (PDF)

The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy

Cell systems, 2018-03, Vol.6 (3), p.314-328.e2

2018

Volltextzugriff (PDF)

The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer

Frontiers in oncology, 2024-02, Vol.14, p.1336546-1336546

2024

Volltextzugriff (PDF)

Genomic landscape of lung adenocarcinomas in different races

Frontiers in oncology, 2022-09, Vol.12, p.946625-946625

2022

Volltextzugriff (PDF)

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

Clinical cancer research, 2010-11, Vol.16 (22), p.5458-5468

2010

Volltextzugriff (PDF)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Journal for immunotherapy of cancer, 2018-11, Vol.6 (1), p.129-129, Article 129

2018

Volltextzugriff (PDF)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR -Mutant Non-Small Cell Lung Cancer

Frontiers in oncology, 2021-11, Vol.11, p.751209

2021

Volltextzugriff (PDF)

Immunotherapies targeting stimulatory pathways and beyond

Journal of hematology and oncology, 2021-05, Vol.14 (1), p.78-78, Article 78

2021

Volltextzugriff (PDF)

Preparation of Cross-Linked Graphene Oxide on Polyethersulfone Membrane for Pharmaceuticals and Personal Care Products Removal

Polymers, 2020-08, Vol.12 (9), p.1921

2020

Volltextzugriff (PDF)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants

Frontiers in oncology, 2022-12, Vol.12, p.1095947-1095947

2022

Volltextzugriff (PDF)

Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy

Frontiers in oncology, 2024-02, Vol.14, p.1306311-1306311

2024

Volltextzugriff (PDF)

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004424

2022

Volltextzugriff (PDF)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e003779

2022

Volltextzugriff (PDF)

1 – 25 von 354

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(318)
Mit Volltextzugriff
(321)

Publikationsform

Sprache

Englisch
(352)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(238)
Life Sciences & Biomedicine
(143)
Oncology
(65)
Physical Sciences
(63)
Humans
(60)
Technology
(60)
Immunotherapy
(36)
Female
(31)
Animals
(30)
Chemistry
(29)
Lung Cancer
(29)
Tumors
(28)
Engineering
(27)
Science & Technology - Other Topics
(27)
Physics
(26)
Cancer
(25)
Male
(24)
Materials Science
(24)
Mice
(23)
Patients
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Next generation of immune checkpoint inhibitors and beyond

Emerging therapeutic agents for advanced non-small cell lung cancer

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Emerging therapeutic agents for lung cancer

Cancer immunotherapy beyond immune checkpoint inhibitors

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Comprehensive Characterization of Alternative Polyadenylation in Human Cancer

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis

The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy

The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer

Genomic landscape of lung adenocarcinomas in different races

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR -Mutant Non-Small Cell Lung Cancer

Immunotherapies targeting stimulatory pathways and beyond

Preparation of Cross-Linked Graphene Oxide on Polyethersulfone Membrane for Pharmaceuticals and Personal Care Products Removal

Editorial: Immunotherapy for NSCLC with oncogenic driver variants

Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy

Suchergebnisse filtern